Control experiments treating a distinct patient-derived cancer cell line HCC827 expressing endogenous oncogenic EGFR (PM-localized) with an established EGFR inhibitor (Tsao et al., 2005) confirmed suppression of wild-type RAS-GTP levels but showed no effect on KRAS-C185S RAS-GTP levels (Figures S3O–S3R). The gene discussed is EGFR; the disease is cancer.